TY - JOUR
T1 - Surgical portosystemic shunts and the Rex bypass in children
T2 - A single-centre experience
AU - Emre, Sukru
AU - Dugan, Christina
AU - Frankenberg, Tamara
AU - Hudgins, Lisa Cooper
AU - Gagliardi, Rosemarie
AU - Artis, A. Tarik
AU - Rodriguez-Laiz, Gonzalo
AU - Gondolesi, Gabriel
AU - Shneider, Benjamin L.
AU - Kerkar, Nanda
PY - 2009
Y1 - 2009
N2 - Objectives: This study aimed to illustrate the indications for, and types and outcomes of surgical portosystemic shunt (PSS) and/or Rex bypass in a single centre. Methods: Data were collected from children with a PSS and/or Rex bypass between 1992 and 2006 at Mount Sinai Medical Center, New York. Results: Median age at surgery was 10.7 years (range 0.3-22.0 years). Indications included: (i) refractory gastrointestinal bleeding in portal hypertension associated with (a) compensated cirrhosis (n = 12), (b) portal vein thrombosis (n = 10), (c) hepatoportal sclerosis (n = 3); (ii) refractory ascites secondary to Budd-Chiari syndrome (n = 3), and (iii) familial hypercholesterolaemia (n = 4). There were 20 distal splenorenal, four portacaval, three Rex bypass, two mesocaval, two mesoatrial and one proximal splenorenal shunts. At the last follow-up (median 2.9 years, range 0.1-14.1 years), one shunt (Rex bypass) was thrombosed. Two patients had died and two had required a liver transplant. These had a patent shunt at last imaging prior to death or transplant. Conclusions: Portosystemic shunts and Rex bypass have been used to manage portal hypertension with excellent outcomes. In selected children with compensated liver disease, PSS may act as a bridge to liver transplantation or represent an attractive alternative.
AB - Objectives: This study aimed to illustrate the indications for, and types and outcomes of surgical portosystemic shunt (PSS) and/or Rex bypass in a single centre. Methods: Data were collected from children with a PSS and/or Rex bypass between 1992 and 2006 at Mount Sinai Medical Center, New York. Results: Median age at surgery was 10.7 years (range 0.3-22.0 years). Indications included: (i) refractory gastrointestinal bleeding in portal hypertension associated with (a) compensated cirrhosis (n = 12), (b) portal vein thrombosis (n = 10), (c) hepatoportal sclerosis (n = 3); (ii) refractory ascites secondary to Budd-Chiari syndrome (n = 3), and (iii) familial hypercholesterolaemia (n = 4). There were 20 distal splenorenal, four portacaval, three Rex bypass, two mesocaval, two mesoatrial and one proximal splenorenal shunts. At the last follow-up (median 2.9 years, range 0.1-14.1 years), one shunt (Rex bypass) was thrombosed. Two patients had died and two had required a liver transplant. These had a patent shunt at last imaging prior to death or transplant. Conclusions: Portosystemic shunts and Rex bypass have been used to manage portal hypertension with excellent outcomes. In selected children with compensated liver disease, PSS may act as a bridge to liver transplantation or represent an attractive alternative.
KW - Compensated cirrhosis
KW - Extrahepatic portal hypertension
KW - Outcome
KW - Surgical shunt
UR - http://www.scopus.com/inward/record.url?scp=66949166077&partnerID=8YFLogxK
U2 - 10.1111/j.1477-2574.2009.00047.x
DO - 10.1111/j.1477-2574.2009.00047.x
M3 - Article
AN - SCOPUS:66949166077
SN - 1365-182X
VL - 11
SP - 252
EP - 257
JO - HPB
JF - HPB
IS - 3
ER -